Evidence map›Paper›PMID 8809041›Full record

ArticleThe Biochemical journal1996

The co-mitogenic combination of transforming growth factor beta 1 and bombesin protects protein kinase C-delta from late-phase down-regulation, despite synergy in diacylglycerol accumulation.

A R Olivier, G Hansra, T R Pettitt, M J Wakelam, P J Parker

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 16 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

A R OlivierProtein Phosphorylation Laboratory, Imperial Cancer Research Fund, London, U.K.
G Hansra
T R Pettitt
M J Wakelam
P J Parker
The Honourable Society of Lincoln's Inn · GBUniversity of Birmingham · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Bombesin induces the down-regulation of protein kinase C-delta (PKC-delta) and PKC-epsilon in Swiss 3T3 cells. Simultaneous addition of transforming growth factor beta 1 (TGF beta 1) selectively blocks PKC-delta down-regulation at mid-S-phase, whereas PKC-epsilon levels continue to decline. Northern blot analysis shows that PKC-epsilon levels could be controlled in part at the level of transcription; PKC-delta mRNA levels remained constant at these later times. Bombesin induces a sustained elevation of some species of diacylglycerol (DAG), consistent with the observed loss of PKC-delta and PKC-epsilon. Interestingly, the combination of bombesin and TGF-beta 1 produces an even greater DAG response. Flow cytometric analysis demonstrates that bombesin induces only 15% of the cells to enter the cell cycle, in contrast to the combination of TGF beta 1 plus bombesin which induces 75-80% of the cells to progress through the cycle. The protection of PKC-delta from down-regulation under conditions of sustained DAG elevation correlates with the mitogenic response and implies that the down-regulation process itself is regulated. Consistent with this, it is demonstrated that bombesin plus TGF beta 1 protects PKC-delta from phorbol ester-induced down-regulation.

Indexed as

3T3 CellsAnimalsBlotting, NorthernBombesinCell DivisionDiglyceridesDrug InteractionsGene Expression Regulation, EnzymologicIsoenzymesKineticsMiceProtein Kinase CProtein Kinase C betaProtein Kinase C-deltaProtein Kinase C-epsilonRNA, MessengerBombesinDiglyceridesIsoenzymesPrkcd protein, mousePrkce protein, mouseProtein Kinase CProtein Kinase C betaProtein Kinase C-deltaProtein Kinase C-epsilonRNA, MessengerTransforming Growth Factor beta

Identifiers

PMID8809041
PMCPMC1217651
OpenAlexW2397129508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.